CDK2 and cancer: Cancer cells rely heavily on CDKs like CDK1, CDK2, and CDK9 for uncontrolled proliferation, whereas normal cells maintain cell cycle control with minimal CDK activity, making them less susceptible to Dinaciclib-induced cytotoxicity.